InvestSMART

Avecho Biotechnology Limited (ASX:AVE)

ALERT: Price-sensitive ASX Announcement for AVE
Current share price for AVE : $0.019 -0.002 (-9.52%)+
Announcement
Release
26 Aug 2026 8:25AM
Price at Release
$0.021
Full Release
download
Summary
Avecho Biotechnology Limited's Appendix 4D and Half-Year Financial Report for the period ending 30 June 2026 highlights a comprehensive financial overview of the company's operations. The company reported a total comprehensive loss of $1,923,629 for the period, compared to a loss of $2,675,960 in the previous year. Revenue from contracts with customers amounted to $59,602, a decrease from $560,069 the previous year. The company received $1,375,397 in research and development tax incentives and other income, while incurring $1,819,144 in research and development expenses. The financial report also details an upfront licensing fee of approximately A$4.8 million from a deal with Sandoz Group AG, classified as a contract liability. Avecho continues to focus on its production and human health segments, with significant emphasis on research and development activities, which are crucial to its business model.
Key Points
  • Total comprehensive loss for the period was $1,923,629.
  • Revenue from contracts with customers decreased to $59,602.
  • Research and development tax incentive income was $1,375,397.
  • Research and development expenses totaled $1,819,144.
  • Upfront licensing fee from Sandoz of A$4.8 million is recognized as a contract liability.
  • Focus on production and human health segments with significant R&D activities.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.